Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

Exclusion Criteria

• •Use of Lovaza (2g/d or more) or high-dose dietary supplement omega-3 oil (4g/d or more) in the past 2 months
• •Use of lipid therapy (statin, ezetimibe, fibrate, BAS, or niacin at therapeutic dose, 1g/d or higher) in the past 3 weeks (washout of prior therapy permitted)
• •Anticipated need to change type or dose of BP medicine (all types allowed), of lipid-active diabetes medication (thiazolidinedione), of oral estrogen (BCP or HRT), or glucocorticoid during the study (16 + 2 weeks = 18 weeks total)
• •Excess ethanol consumption (regular intake \>4 drinks/d, or binges of \>8 drinks at once for men, half these levels for women)
• •Poorly controlled diabetes mellitus (A1c \>9%)
• •History of acute or chronic pancreatitis
• •Use of exenatide (Byetta) or sitagliptin (Januvia), medications believed to increase the risk of acute pancreatitis
• •History of significant unexplained or uncontrolled bleeding or bruising
• •Poorly controlled blood pressure (\>140/90mmHg, with or without treatment)
• •Poorly controlled thyroid disease (TSH outside of normal range)
• •Hepatic disease (ALT \> 2.5x ULN, Dx of hepatitis or cirrhosis)
• •Any contraindication or prior adverse reaction to Lovaza
• •Active cancer (except basal cell or squamous cell skin cancer)
• •Pregnancy, plan/desire to become pregnant, breast feeding
• •Inability or unwillingness to provide informed consent